Compare WGS & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGS | QDEL |
|---|---|---|
| Founded | 2017 | 1979 |
| Country | United States | United States |
| Employees | 1300 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2022 |
| Metric | WGS | QDEL |
|---|---|---|
| Price | $49.52 | $12.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | ★ $120.71 | $28.25 |
| AVG Volume (30 Days) | 1.9M | ★ 2.3M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.35 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,730,200,000.00 |
| Revenue This Year | $29.98 | $3.51 |
| Revenue Next Year | $25.92 | $3.86 |
| P/E Ratio | $1,251.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.21 | $9.92 |
| 52 Week High | $170.87 | $35.58 |
| Indicator | WGS | QDEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 49.37 |
| Support Level | $32.21 | $10.86 |
| Resistance Level | $96.34 | $12.85 |
| Average True Range (ATR) | 3.68 | 0.91 |
| MACD | 1.51 | 0.35 |
| Stochastic Oscillator | 94.11 | 80.50 |
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.